NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026

NAMS•2026-08-26

What the presentations will cover

Data focus on how stable lipoprotein(a) measurements are over the short term during treatment in late-stage trials.

Another presentation will summarize pooled on-treatment lipid-lowering effects across Phase 3 studies, supporting the drug’s overall efficacy profile.

Upcoming ESC Congress presentations

NewAmsterdam Pharma scheduled new analyses from its Phase 3 obicetrapib program for presentation at ESC Congress 2026 in Munich.

Results will be presented in the future, starting Aug. 28, 2026, with additional sessions on Aug. 30-31.

NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026

What the presentations will cover

Upcoming ESC Congress presentations

Related News

Sunshine Biopharma says K1.1 mRNA shows tumor suppression in liver cancer mouse models

Dutch road authority: currently no recall of Teslas in Europe over door handle issue

Berkshire Hathaway’s FlightSafety agrees to buy Acron Technologies’ commercial training unit

Kohl's reports second-quarter sales miss on weak discretionary spending

RPT-ROI-Yen bears, it’s time to recalibrate: Stephen Jen